Deep vein thrombosis

Factor XIa and factor XIIa inhibitors

Active trials are under way testing various agents that target factor XI or factor XII with different mechanisms of action, and for therapeutic and prophylactic indications. These agents have the potential to be associated with a lower risk of bleeding compared with presently available therapies.[231]Xia Y, Hu Y, Tang L. Factor XIa inhibitors as a novel anticoagulation target: recent clinical research advances. Pharmaceuticals (Basel). 2023 Jun 11;16(6):866. https://www.mdpi.com/1424-8247/16/6/866 http://www.ncbi.nlm.nih.gov/pubmed/37375813?tool=bestpractice.com [232]Tashchilova A, Podoplelova N, Sulimov A, et al. New blood coagulation factor XIIa inhibitors: molecular modeling, synthesis, and experimental confirmation. Molecules. 2022 Feb 12;27(4):1234. https://www.mdpi.com/1420-3049/27/4/1234 http://www.ncbi.nlm.nih.gov/pubmed/35209023?tool=bestpractice.com ​​​